Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors
暂无分享,去创建一个
Alessandra Gianoncelli | Giovanni Ribaudo | Maurizio Memo | A. Gianoncelli | G. Ribaudo | Maurizio Memo
[1] A. Blokland,et al. Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation , 2004, Psychopharmacology.
[2] O. Sanders,et al. Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale , 2020, Journal of Alzheimer's disease reports.
[3] Haibin Luo,et al. Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids. , 2019, Bioorganic & medicinal chemistry letters.
[4] Lynn A. Hyde,et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.
[5] J. Lanciego,et al. Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.
[6] Manjinder Singh,et al. Flavones: an important scaffold for medicinal chemistry. , 2014, European journal of medicinal chemistry.
[7] H. Kinney,et al. Caffeine improves the ability of serotonin-deficient (Pet-1−/−) mice to survive episodic asphyxia , 2013, Pediatric Research.
[8] Jian Li,et al. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. , 2017, ACS chemical neuroscience.
[9] K. Reymann,et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents , 2008, Neuropharmacology.
[10] B. Oyinloye,et al. In vitro antioxidant and enzyme inhibitory properties of the n-butanol fraction of Senna podocarpa (Guill. and Perr.) leaf , 2019, Journal of basic and clinical physiology and pharmacology.
[11] Jing Liu,et al. Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease. , 2018, European journal of medicinal chemistry.
[12] Dong I. Lee,et al. Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span , 2018, Neurobiology of Aging.
[13] G. Ribaudo,et al. New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is). , 2016, Current medicinal chemistry.
[14] K. Duodu,et al. Phenolic Composition and Bioactive Properties of Cell Wall Preparations and Whole Grains of Selected Cereals and Legumes , 2014 .
[15] J. Klimeš,et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine , 2014, Expert opinion on drug safety.
[16] G. Oboh,et al. Comparative Effects of Alkaloid Extracts from Aframomum melegueta (Alligator Pepper) and Aframomum danielli (Bastered Melegueta) on Enzymes Relevant to Erectile Dysfunction , 2017, Journal of dietary supplements.
[17] Hui Qi,et al. Dose–response meta‐analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease , 2014, Geriatrics & gerontology international.
[18] G. Oboh,et al. Modulation of some markers of erectile dysfunction and malonaldehyde levels in isolated rat penile tissue with unripe and ripe plantain peels: identification of the constituents of the plants using HPLC , 2017, Pharmaceutical biology.
[19] S. Patra,et al. Development of Xanthine Based Inhibitors Targeting Phosphodiesterase 9A , 2017 .
[20] Xinhai Zhu,et al. Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor , 2015, Molecular Pharmacology.
[21] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[22] H. Rosenbrock,et al. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP , 2012, Neuropharmacology.
[23] V. Lemos,et al. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. , 2009, European journal of pharmacology.
[24] M. Memo,et al. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach , 2019, Natural product research.
[25] C. Lugnier,et al. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. , 2005, Planta medica.
[26] F. Leonetti,et al. Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds , 2018, Molecules.
[27] G. Ribaudo,et al. Isoflavones from Maclura pomifera: structural elucidation and in silico evaluation of their interaction with PDE5 , 2017, Natural product research.
[28] Yuren Jiang,et al. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease. , 2017, Bioorganic & medicinal chemistry letters.
[29] G. Ribaudo,et al. Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease. , 2019, Bioorganic chemistry.
[30] Sai-Sai Xie,et al. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. , 2015, European journal of medicinal chemistry.
[31] Wei Zhang,et al. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[32] G. Ribaudo,et al. Semi-synthetic derivatives of natural isoflavones from Maclura pomifera as a novel class of PDE-5A inhibitors. , 2015, Fitoterapia.
[33] G. Ribaudo,et al. An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds. , 2017, Current medicinal chemistry.
[34] Manjinder Singh,et al. Hybrids: a new paradigm to treat Alzheimer’s disease , 2015, Molecular Diversity.
[35] G. Ribaudo,et al. The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases. , 2017, ACS chemical neuroscience.
[36] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[37] M. Díaz-Ríos,et al. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. , 2014, Life sciences.
[38] A. Herman. Caffeine’s Mechanisms of Action and Its Cosmetic Use , 2012, Skin Pharmacology and Physiology.
[39] A. Kappo,et al. Ocimum gratissimum Linn. Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats , 2019, BMC Complementary and Alternative Medicine.
[40] G. Grześk,et al. Role of acetylcholine and calcium ions in three vascular contraction models: Angiotensin II, phenylephrine and caffeine. , 2012, Experimental and therapeutic medicine.
[41] G. Oboh,et al. Extracts from Almond (Terminalia catappa) leaf and stem bark mitigate the activities of crucial enzymes and oxidative stress associated with hypertension in cyclosporine A-stressed rats. , 2020, Journal of food biochemistry.
[42] R. Young,et al. Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. , 2010, Bioorganic & medicinal chemistry letters.
[43] T. Mohamed,et al. Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations. , 2013, Bioorganic & medicinal chemistry letters.
[44] Huyuan Yang,et al. What Is Already Known about This Subject What This Study Adds , 2022 .
[45] M. Memo,et al. Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist , 2020, ACS chemical neuroscience.
[46] S. R. Salian,et al. Design and Microwave Assisted Synthesis of Coumarin Derivatives as PDE Inhibitors , 2016, International journal of medicinal chemistry.
[47] O. Forlenza,et al. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease , 2009, European Archives of Psychiatry and Clinical Neuroscience.
[48] G. Ribaudo,et al. Antioxidant Potential of Psychotropic Drugs: From Clinical Evidence to In Vitro and In Vivo Assessment and toward a New Challenge for in Silico Molecular Design , 2020, Antioxidants.
[49] R. Castellani,et al. Alzheimer disease. , 2010, Disease-a-month : DM.
[50] E. Karran,et al. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues , 2010, Neuropharmacology.
[51] M. Memo,et al. 2-(3,4-Dihydroxyphenyl)-4-(2-(4-nitrophenyl)hydrazono)-4H-chromene-3,5,7-triol , 2020, Molbank.
[52] G. Ribaudo,et al. 5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one , 2018, Molbank.
[53] Astrid Nehlig,et al. Is caffeine a cognitive enhancer? , 2010, Journal of Alzheimer's disease : JAD.
[54] M. Memo,et al. A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration , 2021, Pharmaceuticals.
[55] K. Gołembiowska,et al. The Effect of Adenosine A2A Receptor Antagonists on Hydroxyl Radical, Dopamine, and Glutamate in the Striatum of Rats with Altered Function of VMAT2 , 2012, Neurotoxicity Research.
[56] G. Oboh,et al. Modulatory effect of quercetin and its glycosylated form on key enzymes and antioxidant status in rats penile tissue of paroxetine-induced erectile dysfunction. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[57] M. Pohanka. The perspective of caffeine and caffeine derived compounds in therapy. , 2015, Bratislavske lekarske listy.
[58] N. Tsuno,et al. Donepezil in the treatment of patients with Alzheimer’s disease , 2009, Expert review of neurotherapeutics.
[59] Manjinder Singh,et al. Exploration of multi-target potential of chromen-4-one based compounds in Alzheimer's disease: Design, synthesis and biological evaluations. , 2017, Bioorganic & medicinal chemistry.
[60] T. Nicholas,et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. , 2014, Current Alzheimer research.
[61] Laura Orian,et al. Major Depressive Disorder and Oxidative Stress: In Silico Investigation of Fluoxetine Activity against ROS , 2019, Applied Sciences.
[62] M. Pohanka. Alzheimer´s disease and oxidative stress: a review. , 2013, Current medicinal chemistry.
[63] Marine Peuchmaur,et al. β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy. , 2021, Journal of medicinal chemistry.
[64] G. Ribaudo,et al. Psychiatric Disorders and Oxidative Injury: Antioxidant Effects of Zolpidem Therapy disclosed In Silico , 2019, Computational and structural biotechnology journal.
[65] M. Memo,et al. Combinatorial library generation, molecular docking and molecular dynamics simulations for enhancing the isoflavone scaffold in phosphodiesterase inhibition , 2020 .
[66] T. Hartmann,et al. Unique Role of Caffeine Compared to Other Methylxanthines (Theobromine, Theophylline, Pentoxifylline, Propentofylline) in Regulation of AD Relevant Genes in Neuroblastoma SH-SY5Y Wild Type Cells , 2020, International journal of molecular sciences.
[67] Liang Shen,et al. Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease , 2011, Molecules.
[68] C. J. Schmidt. Phosphodiesterase inhibitors as potential cognition enhancing agents. , 2010, Current topics in medicinal chemistry.
[69] A. O. Ademiluyi,et al. Phenolic analysis and erectogenic function of African Walnut (Tetracarpidium conophorum) seeds: The impact of the seed shell on biological activity. , 2019, Journal of food biochemistry.
[70] M. Štrucl,et al. Cognitive and autonomic dysfunction in presymptomatic and early Huntington’s disease , 2014, Journal of Neurology.
[71] N. K. Simas,et al. Phytochemical and allelopathic studies of Terminalia catappa L. (Combretaceae) , 2012 .